Skip to main content

Table 4 Comparison of the clinicopathological features of 30 CRC patients according to the presence of NDRG2 methylation

From: Promoter methylation correlates with reduced NDRG2expression in advanced colon tumour

Age (yrs):    
  Number of CRC
with NDRG2 methylation (%)
Number of CRC
without NDRG2 methylation (%)
p value
   Age <50 4 (13.3) 5 (16.6) ns
   Age >50 4 (13.3) 17 (56.6)  
Gender    
   Male 4 (26.7) 11 (73.3) ns
   Female 4 (26.7) 11 (73.3)  
CRC:    
   Familiar 2 (25.0) 6 (75.0) ns
   Sporadic 6 (27.3) 16 (72.7)  
Tumour location:    
   Proximal colon 2 (22.2) 7 (77.7) ns
   Distal colon 6 (28.6) 15 (71.4)  
AJCC stage:    
0 0 1 (4.8) ns*
I 1 (12.5) 2 (9.5)  
IIa 1 (12.5) 7 (33.3)  
IIIb 0 3 (14.3)  
IV 6 (75.0) 8 (38.1) < 0,05^
MSI status 1    
   High 1 (25.0) 3 (75.0) ns
   Low 1 (33.4) 2 (66.7)  
   Stable 6 (27.3) 17 (72.7)  
  1. Fisher exact test (2-tail); *Pearson Chi-square; ^Z test only for IV AJCC' stage
  2. 1Microsatellite instability (MSI) was determined by the mobility shift of PCR products using CC-MSI kit (AB Analitica s.r.l., Padova, Italy, http://www.abanalitica.com), that include the Bethesda panel microsatellite (BAT25, BAT26, D5S346, D17S250 and D2S123) and other four mononucleotide microsatellite loci (NR21, NR24, BAT40 and TGFβRII), in tumours. Tumours showing instability in four or more markers were classified as high MSI, those showing it in two marker as low MSI, and those showing no instability as microsatellite-stable.